0000000000539118

AUTHOR

Manuel Arrojo Romero

0000-0002-5609-7134

showing 2 related works from this author

Duration of untreated psychosis in first-episode psychosis is not associated with common genetic variants for major psychiatric conditions: results f…

2021

The EU-GEI Project is funded by the European Community’s Seventh Framework Programme under grant agreement No. HEALTH-F2-2010–241909 (Project EU-GEI).

Bipolar DisorderTime FactorsIntelligenceGenome-wide association studyDETERMINANTSpsychosi0302 clinical medicineInterquartile rangeSettore MED/48 -Scienze Infermierist. e Tecn. Neuro-Psichiatriche e Riabilitat.IMPUTATIONpolygenic scorepsychosis0303 health sciencesConfoundingEuropePsychiatry and Mental healthgenome-wide association studieSchizophreniaMajor depressive disorderlipids (amino acids peptides and proteins)Case-Control Studieduration of untreated psychosisBrazilHumanAdultPsychosismedicine.medical_specialtycongenital hereditary and neonatal diseases and abnormalitiesTime FactorAcademicSubjects/MED00810DISORDERS1ST EPISODEILLNESSPsychotic Disorderduration of untreated psychosi03 medical and health sciencesInternal medicinemedicineHumansBipolar disorderGENOME-WIDE ASSOCIATIONSettore MED/25 - PsichiatriaMETAANALYSIS030304 developmental biologyDepressive Disorder Majorbusiness.industryCOMPONENTSTREATMENT DELAYmedicine.diseaseTRANSTORNO BIPOLARschizophreniapolygenic scoresPsychotic DisordersCase-Control Studiesdupgenome-wide association studiesbusiness030217 neurology & neurosurgeryRegular ArticlesGenome-Wide Association Study
researchProduct

Review of Pharmacokinetics and Pharmacogenetics in Atypical Long-Acting Injectable Antipsychotics

2021

Over the last two decades, pharmacogenetics and pharmacokinetics have been increasingly used in clinical practice in Psychiatry due to the high variability regarding response and side effects of antipsychotic drugs. Specifically, long-acting injectable (LAI) antipsychotics have different pharmacokinetic profile than oral formulations due to their sustained release characteristics. In addition, most of these drugs are metabolized by CYP2D6, whose interindividual genetic variability results in different metabolizer status and, consequently, into different plasma concentrations of the drugs. In this context, there is consistent evidence which supports the use of therapeutic drug monitoring (TD…

medicine.medical_treatmentPopulationAripiprazolePharmaceutical ScienceContext (language use)ReviewPharmacology030226 pharmacology & pharmacy03 medical and health sciences0302 clinical medicinearipiprazolePharmacy and materia medicamedicineAntipsychoticsPaliperidoneeducationAntipsychoticPopulation pharmacokinetic modelspharmacogeneticseducation.field_of_studyRisperidonerisperidonemedicine.diagnostic_testbusiness.industryCYP2D6PaliperidoneRisperidoneLAIRS1-441antipsychoticsTherapeutic drug monitoringpopulation pharmacokinetic modelsPharmacogeneticsAripiprazolebusinesspaliperidone030217 neurology & neurosurgeryPharmacogeneticsmedicine.drug
researchProduct